NewsAussie pharma CSL in talks to buy Swiss firm...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

-

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor Pharma is a Swiss pharma company.
Analysts predict that as CSL buys Vifor Pharma it will be able to expand on its current portfolio to include manufacturing of drugs for kidney and heart disease. Currently, CSL pharmaceutical company is the largest manufacturer of blood plasma treatments.
The deal has been in the works since early 2021, but as the talks have become serious, Vifor Pharma’s shares have risen by almost a fifth, closing in at a 21% increase in the Swiss index.
CSL pharmaceutical company had seen a dip in collections for plasma due to COVID-19 pandemic restrictions. This is due to the fact that it is dependent on people coming for blood to be purchased by the company.
As CSL buys Vifor pharma, they will gain the ability to expand on their kidney transplant franchise, which is currently in its infancy stage. However, this will be a step away from their focus on the therapeutic area of medicine. Both companies have stated that they will not be commenting on the deal.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 High-Impact Careers Defining the Future of Life Sciences

Executive Summary The life sciences workforce in 2026 is being reshaped by AI integration, advanced therapeutics, regulatory complexity, and commercialization...

In a late-stage trial, Intellia’s gene treatment for rare condition reduces swelling attacks

Intellia Therapeutics has announced that its experimental gene-editing drug reduced the number of swelling attacks in patients with a...

Boehringer Reports Phase 3 Data on Survodutide Showing 16.6% Weight Loss at Week 76

Boehringer Ingelheim has reported results from a phase 3 clinical trial of its glucagon/GLP-1 dual agonist, survodutide, in adults...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you